Data mining and safety analysis of voriconazole in patients with a hematological malignant tumor based on the FAERS database: differences between children and adults
ObjectiveVoriconazole is a broad-spectrum antifungal agent. It is used widely for the prevention and treatment of invasive fungal infections in patients with a hematological malignancy, but studies on its safety in this population are scarce. We assessed the adverse drug events (ADEs) of voriconazol...
Saved in:
Main Authors: | Hao Li, Manxue Jiang, Xiaona Pan, Lingti Kong |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2025-01-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1524702/full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Post-Marketing Pharmacovigilance of Canakinumab from the FDA Adverse Event Reporting System (FAERS)
by: Weidong Zhang, et al.
Published: (2025-01-01) -
Bioinformatic characterization of STING expression in hematological malignancies reveals association with prognosis and anti-tumor immunity
by: Xiang-mei Wen, et al.
Published: (2025-02-01) -
Voriconazole-induced periostitis in the hand
by: Gurbinder Singh, et al.
Published: (2025-03-01) -
Safety profiles of sevoflurane in pediatric patients: a real-world pharmacovigilance assessment based on the FAERS database
by: Chuang Yang, et al.
Published: (2025-02-01) -
Knowledge on the Use of Biosimilars in Hematological Malignancies Amongst Health Care Workers at a Tertiary Hospital in Northeast Nigeria
by: Rufai A. Dachi, et al.
Published: (2024-07-01)